Collection 4 (Sep 2023 - Aug 2024) Articles

Articles
Dyslipidemia management in women of reproductive potential: An expert clinical consensus from the national lipid association
Agarwala A, Dixon DL, Gianos E, et al.
Journal:
J Clin Lipidol

First published: May 30, 2024 DOI: 10.1016/j.jacl.2024.05.005
View
- Share
Articles
Current US prevalence of myocardial injury patterns and clinical outcomes among hospitalised patients with familial hypercholesterolaemia: insight from the National Inpatient Sample-a retrospective cohort study
Kumi D, Narh JT, Odoi SM, et al.
Journal:
BMJ Open

First published: May 28, 2024 DOI: 10.1136/bmjopen-2023-077839
View
- Share
Articles
Cardiovascular risk factors and aortic valve stenosis: towards 10-year absolute risk charts for primary prevention
Kjeldsen EW, Thomassen JQ, Rasmussen KL, et al.
Journal:
Eur J Prev Cardiol

First published: May 22, 2024 DOI: 10.1093/eurjpc/zwae177
View
- Share
Articles
Association of Lipoprotein (a) and Standard Modifiable Cardiovascular Risk Factors With Incident Myocardial Infarction: The Mass General Brigham Lp(a) Registry
Shiyovich A, Berman AN, Besser SA, et al.
Journal:
J Am Heart Assoc

First published: May 18, 2024 DOI: 10.1161/JAHA.123.034493
View
- Share
Articles
Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial
Wright RS, Raal FJ, Koenig W, et al.
Journal:
Cardiovasc Res

First published: May 16, 2024 DOI: 10.1093/cvr/cvae109
View
- Share
Articles
Coronary artery calcium in 2023: Guidelines for LDL-C goals, non-statin therapies, and aspirin use
Soroosh GP, Tasdighi E, Adhikari R, et al.
Journal:
Prog Cardiovasc Dis

First published: May 15, 2024 DOI: 10.1016/j.pcad.2024.05.004
View
- Share
Articles
Advancements in risk stratification and management strategies in primary cardiovascular prevention
Barkas F, Sener YZ, Golforoush PA, et al.
Journal:
Atherosclerosis

First published: May 14, 2024 DOI: 10.1016/j.atherosclerosis.2024.117579
View
- Share
Articles
Impact of Lipoprotein(a) Levels on Cardiovascular Risk Estimation
Masson W, Waisman G, Corral P, et al.
Journal:
High Blood Press Cardiovasc Prev

First published: May 13, 2024 DOI: 10.1007/s40292-024-00649-x
View
- Share
Articles
Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research
Kamstrup PR, Neely RDG, Nissen S, et al.
Journal:
Eur J Prev Cardiol

First published: May 11, 2024 DOI: 10.1093/eurjpc/zwae032
View
- Share
Articles
Consensus document on diagnosis and management of familial hypercholesterolemia from the Italian Society for the Study of Atherosclerosis (SISA)
Tarugi P, Bertolini S, Calandra S, et al.
Journal:
Nutr Metab Cardiovasc Dis

First published: May 7, 2024 DOI: 10.1016/j.numecd.2024.05.002
View
- Share
Articles
Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention
Sniderman AD, Dufresne L, Pencina KM, et al.
Journal:
Eur Heart J

First published: May 3, 2024 DOI: 10.1093/eurheartj/ehae258
View
- Share
Articles
Obicetrapib on Top of Maximally Tolerated Lipid-Modifying Therapies in Participants With or at High Risk for Atherosclerotic Cardiovascular Disease: Rationale and Designs of BROADWAY and BROOKLYN
Nicholls SJ, Nelson AJ, Ditmarsch M, et al.
Journal:
Am Heart J

First published: May 3, 2024 DOI: 10.1016/j.ahj.2024.05.002
View
- Share

1 2 3 4 5 6 … 12

Collection 4 (Sep 2023 - Aug 2024) Articles

Articles

Dyslipidemia management in women of reproductive potential: An expert clinical consensus from the national lipid association

Agarwala A, Dixon DL, Gianos E, et al.

Articles

Current US prevalence of myocardial injury patterns and clinical outcomes among hospitalised patients with familial hypercholesterolaemia: insight from the National Inpatient Sample-a retrospective cohort study

Kumi D, Narh JT, Odoi SM, et al.

Articles

Cardiovascular risk factors and aortic valve stenosis: towards 10-year absolute risk charts for primary prevention

Kjeldsen EW, Thomassen JQ, Rasmussen KL, et al.

Articles

Association of Lipoprotein (a) and Standard Modifiable Cardiovascular Risk Factors With Incident Myocardial Infarction: The Mass General Brigham Lp(a) Registry

Shiyovich A, Berman AN, Besser SA, et al.

Articles

Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial

Wright RS, Raal FJ, Koenig W, et al.

Articles

Coronary artery calcium in 2023: Guidelines for LDL-C goals, non-statin therapies, and aspirin use

Soroosh GP, Tasdighi E, Adhikari R, et al.

Articles

Advancements in risk stratification and management strategies in primary cardiovascular prevention

Barkas F, Sener YZ, Golforoush PA, et al.

Articles

Impact of Lipoprotein(a) Levels on Cardiovascular Risk Estimation

Masson W, Waisman G, Corral P, et al.

Articles

Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research

Kamstrup PR, Neely RDG, Nissen S, et al.

Articles

Consensus document on diagnosis and management of familial hypercholesterolemia from the Italian Society for the Study of Atherosclerosis (SISA)

Tarugi P, Bertolini S, Calandra S, et al.

Articles

Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention

Sniderman AD, Dufresne L, Pencina KM, et al.

Articles

Obicetrapib on Top of Maximally Tolerated Lipid-Modifying Therapies in Participants With or at High Risk for Atherosclerotic Cardiovascular Disease: Rationale and Designs of BROADWAY and BROOKLYN

Nicholls SJ, Nelson AJ, Ditmarsch M, et al.

Articles

Dyslipidemia management in women of reproductive potential: An expert clinical consensus from the national lipid association

Agarwala A, Dixon DL, Gianos E, et al.

Share

Articles

Current US prevalence of myocardial injury patterns and clinical outcomes among hospitalised patients with familial hypercholesterolaemia: insight from the National Inpatient Sample-a retrospective cohort study

Kumi D, Narh JT, Odoi SM, et al.

Share

Articles

Cardiovascular risk factors and aortic valve stenosis: towards 10-year absolute risk charts for primary prevention

Kjeldsen EW, Thomassen JQ, Rasmussen KL, et al.

Share

Articles

Association of Lipoprotein (a) and Standard Modifiable Cardiovascular Risk Factors With Incident Myocardial Infarction: The Mass General Brigham Lp(a) Registry

Shiyovich A, Berman AN, Besser SA, et al.

Share

Articles

Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial

Wright RS, Raal FJ, Koenig W, et al.

Share

Articles

Coronary artery calcium in 2023: Guidelines for LDL-C goals, non-statin therapies, and aspirin use

Soroosh GP, Tasdighi E, Adhikari R, et al.

Share

Articles

Advancements in risk stratification and management strategies in primary cardiovascular prevention

Barkas F, Sener YZ, Golforoush PA, et al.

Share

Articles

Impact of Lipoprotein(a) Levels on Cardiovascular Risk Estimation

Masson W, Waisman G, Corral P, et al.

Share

Articles

Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research

Kamstrup PR, Neely RDG, Nissen S, et al.

Share

Articles

Consensus document on diagnosis and management of familial hypercholesterolemia from the Italian Society for the Study of Atherosclerosis (SISA)

Tarugi P, Bertolini S, Calandra S, et al.

Share

Articles

Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention

Sniderman AD, Dufresne L, Pencina KM, et al.

Share

Articles

Obicetrapib on Top of Maximally Tolerated Lipid-Modifying Therapies in Participants With or at High Risk for Atherosclerotic Cardiovascular Disease: Rationale and Designs of BROADWAY and BROOKLYN

Nicholls SJ, Nelson AJ, Ditmarsch M, et al.

Share